BRAF and melanoma: In this single-center retrospective cohort study, we further analyzed the antitumor activity and safety of triple-targeted therapy (TTT): REGO + BRAF/MEKi, specifically in the AJCC stage IV-M1dBRAF- and NRAS-mutant melanoma patients, refractory to standard-of-care.